Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Superior Group of Companies Q4 2025 Earnings Call - Back-end weighted growth, margin lift and AI-driven contact center pivot
Superior posted a muted top line but a noticeable bottom-line recovery in Q4 2025. Consolidated revenue was $147 million, up 1% year-over-year and up 6% sequentially, while EBITDA rose to $8.6 million...
- Consolidated revenue was $147.0 million in Q4 2025, up 1% year-over-year and up 6% sequentially, confirming management’s back-end weighted cadence thesis.
- EBITDA rose to $8.6 million from $7.3 million a year earlier, a 19% increase, and EBITDA margin expanded 90 basis points to 5.9%.
- Diluted EPS nearly doubled to $0.23 in Q4 2025, up from $0.13 in the year-ago quarter.
- +15 more takeaways
Cryoport Q4 & FY2025 Earnings Call - Spring-loaded clinical pipeline sets up commercial revenue surge
Cryoport closed 2025 with a clean beat and a forward-looking posture. Continuing-operations revenue was $176.2 million, above prior guidance, driven by a 29% jump in commercial cell and gene therapy r...
- Continuing-operations revenue for FY2025 was $176.2 million, above the high end of prior guidance.
- Full-year commercial cell and gene therapy revenue rose 29% year-over-year to a record $33.4 million, now representing about 20% of total revenue.
- Clinical trial revenue increased 14% year-over-year to $47.1 million; Cryoport supported a record 760 clinical trials and 20 commercial therapies at year end.
- +11 more takeaways
Evolus Q4 and Full Year 2025 Earnings Call - Portfolio Rebate and Evolysse Launch Set Stage for 2026 Profitability
Evolus closed 2025 with momentum and a clear pivot: double-digit top-line growth, tighter cost discipline, and an explicit plan to use a portfolio rebate and product rollouts to push accounts deeper i...
- Top-line and product mix: Q4 2025 global net revenue was $90.3 million, with full-year 2025 revenue of $297.2 million, up 12% year-over-year and marking six consecutive years of double-digit growth.
- Jeuveau strength: Jeuveau accounted for $83.1 million of Q4 revenue, and management says Jeuveau holds roughly 14% U.S. toxin market share, with continued unit share gains even in a soft procedural environment.
- Evolysse early traction: Evolysse generated $7.2 million in Q4 revenue, more than 3,000 purchasing accounts to date, and management plans a broader sampling and experience program in Q2 2026 to accelerate adoption.
- +13 more takeaways
Arcturus Therapeutics Q4 2025 Earnings Call - Kicking off a 12-week CF Phase 2 as OTC moves to Type C regulatory clarity
Arcturus is narrowing its focus and putting real weight behind two rare disease programs. The company will initiate a 12-week Phase 2 study of ARCT-032 for cystic fibrosis in H1 2026, starting the coh...
- Arcturus will initiate dosing for a 12-week Phase 2 study of ARCT-032 (CF mRNA therapeutic) in H1 2026, enrolling up to 20 Class 1 CF patients across U.S. and international sites.
- The fourth cohort will start at 10 mg with the protocol preserving flexibility to escalate to 15 mg if needed; safety and tolerability were observed at 15 mg in prior cohorts.
- Study design upgrades aim to tighten baseline stability and improve signal detection, including requiring reproducible baseline spirometry before enrollment.
- +11 more takeaways
B&G Foods Q4 Fiscal 2025 Earnings Call - Portfolio reshaping pivots out Green Giant frozen to fund higher-margin broths and simplify the company
B&G Foods used this quarter’s results to press the accelerator on portfolio reshaping, selling the Green Giant US frozen business to Seneca and signing to buy College Inn and Kitchen Basics broths fro...
- B&G closed the sale of Green Giant US Frozen to Seneca Foods, receiving approximately $63.2 million in proceeds, and retained a co-pack manufacturing arrangement in Irapuato, Mexico.
- The Green Giant US divestiture removes roughly $203 million of net sales year-over-year from the company, with Seneca co-pack volumes expected to generate about $80 million of revenue from March through fiscal year-end and roughly $100 million on an annualized run-rate, with modest profit for B&G.
- Green Giant Canada divestiture remains pending regulatory approval in Canada, expected to close in Q2 fiscal 2026; related impairments were recorded earlier in the year, including a $27.8 million pre-tax impairment in Q3 and $0.7 million in Q4 for assets held for sale.
- +11 more takeaways
Quantum-Si Q4 2025 Earnings Call - Announces $425,000 Proteus, pivots 2026 to a transition year focused on launch
Quantum-Si used this call to recast 2026 as a deliberate transition year, trading near-term instrument revenue for a concentrated push to launch Proteus at year-end. Management announced a $425,000 li...
- Company frames 2026 as a transition year, prioritizing Proteus development and market preparation over near-term Platinum Pro instrument sales.
- Proteus list price announced at $425,000, released early to enable customer budgeting and channel planning, but no secured orders disclosed.
- Revenue pressure persists: Q4 2025 revenue of $451,000, full-year 2025 revenue of $2.4 million, and management expects roughly $1 million in revenue for 2026.
- +12 more takeaways
Crexendo Q4 2025 Earnings Call - Adds ESI to Push Toward $100M After Profitable Double-Digit Organic Growth
Crexendo closed 2025 with a clean finance story, double-digit organic growth and sustained profitability, then moved quickly to buy scale. The company reported $68.2 million in revenue for the year, 1...
- Full year 2025 revenue $68.2 million, up 12% year-over-year, with Q4 revenue $18.1 million, up 11% year-over-year.
- Crexendo reported net income of $5.1 million for 2025, and non-GAAP net income of $11.4 million, continuing a string of profitable quarters, including 10 consecutive GAAP profitable quarters.
- Quarterly non-GAAP net income was $2.8 million, adjusted EBITDA for Q4 was $2.8 million or 15.3% of revenue, and adjusted EBITDA for the year was $11.2 million or 17% of revenue.
- +13 more takeaways
Rigel Pharmaceuticals Q4 2025 Earnings Call - R289 posts early 33% RBCTI in higher-dose cohorts, company profitable but GAAP gains masked by a large tax allowance release
Rigel closed 2025 with a sharp commercial inflection and a development story that matters. Net product sales hit $232 million for the year, Q4 net product sales were $65.4 million, and management guid...
- Commercial momentum: 2025 net product sales of $232 million, up $87 million or 60% versus 2024; Q4 net product sales were $65.4 million, up 41% year-over-year.
- Product mix in Q4: TAVALISSE $45.6M (up 47% YoY), GAVRETO $10.2M (up 27% YoY), REZLIDHIA $9.6M (up 29% YoY).
- Total Q4 revenue was $69.8 million, which included $4.4M of collaboration/contract revenues and product sales netted of estimated allowances of $19M.
- +12 more takeaways
NeuroPace Q4 2025 Earnings Call - RNS Growth Fuels Path to Profitability, IGE PMA Now in FDA Review
NeuroPace closed 2025 with clear commercial momentum in its core RNS business, reporting Q4 revenue of $26.6 million, full-year revenue of $100 million, and sustained RNS gross margins above 80%. Mana...
- Q4 2025 revenue $26.6M, up 24% year over year, full-year 2025 revenue $100M, up 25% versus 2024.
- RNS System revenue $22.4M in Q4, up 26% year over year, with second half 2025 RNS growth at 29%.
- Company reiterates full-year 2026 revenue guidance of $98M to $100M, assuming 20% to 22% core RNS growth, excluding any IGE contribution.
- +12 more takeaways
SoundThinking Q4 2025 Earnings Call - 15% ARR Growth Target Sets 2026 as Inflection Point Despite Revenue Timing Headwinds
SoundThinking closed 2025 with record revenue of $104.1 million, ARR of $95.4 million, and maintained double-digit adjusted EBITDA margins. Management is betting 2026 will be the inflection year, targ...
- Record full-year revenue of $104.1 million for 2025, up 2% versus 2024.
- ARR exited 2025 at $95.4 million, with management targeting approximately 15% net ARR growth in 2026, or roughly $14.6 million of ARR added, net of about $3.1 million attrition.
- GAAP revenue guidance for 2026 was lowered to $109 million to $111 million from a prior $114 million to $116 million range, due to timing delays on two expected bookings.
- +11 more takeaways